Other substances

Bicalutamide

A non-steroid anti-androgen drug.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
4
 AI-suggested references
3
 Clinical trials

General information

Bicalutamide is a synthetic non-steroid cytosolic androgen receptor competitive inhibitor (NCIt). It is used in the prostate cancer treatment (DrugBank).

Bicalutamide on PubChem
Bicalutamide on Wikipedia

Marketed as

BICALUTAMIDE; CASODEX

 

Structure image - Bicalutamide

CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O

Supporting references

Link Tested on Impact factor Notes Publication date
Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
3CLpro Small molecule Enzyme assay In vitro In silico 		in silico; in vitro enzyme assay 4.00

Displayed inhibitory activity against SARS-CoV-2 3C-like protease in vitro (over 30% at 50 μM). More accurate measurements are needed, however.

 Nov/30/2020

AI-suggested references

Link Publication date
In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
Apr/03/2022
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data.
Jul/09/2020
Repurposing Cancer Drugs for COVID-19.
Feb/24/2021
Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
Oct/21/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04509999 Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection Withdrawn Phase 3 Oct/26/2020 Jun/30/2021
  • Alternative id - IRB202001669-A|OCR38162
  • Interventions - Drug: Bicalutamide 150 Mg Oral Tablet|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years to 99 Years   (Adult, Older Adult)
  • Outcome measures - Proportion x 100 = percent of patients with improved COVID-19 symptoms
NCT04652765 Camostat With Bicalutamide for COVID-19 Terminated Phase 1 Feb/03/2021 Sep/15/2021
  • Alternative id - COV2005|IRB00254142
  • Interventions - Drug: Camostat Mesilate|Drug: Bicalutamide 150 mg
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Johns Hopkins Hospital, Baltimore, Maryland, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 6
  • Age - 60 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of participants requiring hospitalization|Number of participants experiencing symptoms|Number of drug-related adverse events|Number of drug-related serious adverse events|All-cause mortality
NCT04374279 Trial to Promote Recovery From COVID-19 With Endocrine Therapy Withdrawn Phase 2 Apr/01/2021 Jan/01/2022
  • Alternative id - COV2003|IRB00249425
  • Interventions - Drug: Bicalutamide 150 Mg Oral Tablet
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Johns Hopkins Hospital, Baltimore, Maryland, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Percentage of participants who have clinical improvement at day 7 after randomization|All-cause mortality|Duration of hospitalization|Percentage of patients needing upgrade to the intermediate care unit (IMC)|Duration of IMC stay|Percentage of patients needing upgrade to the intensive care unit (ICU)|Duration of ICU stay|Number of participants requiring mechanical ventilation|Duration of mechanical ventilation|Number of participants experiencing adverse events
Export (.csv)